SCHEMBL1704705

SCHEMBL1704705

CC(C(=O)O)c1ccc(CN2CCN(C(=O)OC(C)(C)C)[C@@H](C)C2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 4/20 0.44
CCR1 P32246 1/20 0.42
GPR119 Q8TDV5 2/20 0.42
MGLL Q99685 1/20 0.42
AGTR2 P50052 1/20 0.39
SETD7 Q8WTS6 1/20 0.39
PTGS1 P23219 3/20 0.39
PTGS2 P35354 3/20 0.39
LMNA P02545 2/20 0.39
CYP2C9 P11712 2/20 0.39
AKR1C3 P42330 2/20 0.39
CXCR1 P25024 2/20 0.39
CXCR2 P25025 2/20 0.39
ALB P02768 1/20 0.39
ESR1 P03372 1/20 0.39
ALOX5 P09917 1/20 0.39
RARB P10826 1/20 0.39
ADRB3 P13945 1/20 0.39
NFKB1 P19838 1/20 0.39
HTR2A P28223 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4185696 0.90 CCR1 (0.43) PTGDR2CCR1GPR119MGLLAGTR2
SCHEMBL4609198 0.86 CCR1 (0.40) PTGDR2CCR1GPR119MGLLAGTR2
SCHEMBL3664004 0.85 MGLL (0.49) PTGDR2CCR1GPR119MGLLAGTR2
SCHEMBL7968974 0.85 MGLL (0.49) PTGDR2CCR1GPR119MGLLAGTR2
SCHEMBL3664002 0.85 MGLL (0.49) PTGDR2CCR1GPR119MGLLAGTR2
SCHEMBL4625997 0.84 PTGDR2 (0.52) PTGDR2CCR1GPR119MGLLSETD7
SCHEMBL1704091 0.84 PTGDR2 (0.52) PTGDR2CCR1GPR119MGLLSETD7
SCHEMBL29269207 0.84 CCR1 (0.47) PTGDR2CCR1GPR119MGLLSETD7
SCHEMBL29269210 0.84 CCR1 (0.47) PTGDR2CCR1GPR119MGLLSETD7
SCHEMBL29269208 0.84 CCR1 (0.47) PTGDR2CCR1GPR119MGLLSETD7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130317041-A1 COMPOUNDS GLAXO GROUP LIMITED (GB) 2013-11-28 US disclosed
US-8536182-B2 Benzylpiperazine derivatives and their medical use GLAXO GROUP LIMITED (GB) 2013-09-17 US disclosed
EP-1907374-B1 Benzylpiperazine derivatives useful for the treatment of gastrointestinal disorders GLAXO GROUP LTD (GB) 2012-08-22 EP disclosed
EP-2441763-A1 Benzylpiperazine derivatives useful for the treatment of gastrointestinal disorders Glaxo Group Limited (GB) 2012-04-18 EP disclosed
US-20090054456-A1 BENZYLPIPERAZINE DERIVATIVES AND THEIR MEDICAL USE GLAXO GROUP LIMITED (GB) 2009-02-26 US disclosed
EP-1907374-A2 COMPOUNDS GLAXO GROUP LIMITED (GB) 2008-04-09 EP disclosed
WO-2007012479-A2 BENZYLPIPERAZINE DERIVATES AND THEIR MEDICAL USE GLAXO GROUP LIMITED (GB) 2007-02-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054456-A1 BENZYLPIPERAZINE DERIVATIVES AND THEIR MEDICAL USE GPR68, GPR88, GPR55 PTGDR2 37/4885CCR1 1073/4885GPR119 12/4885
US-20130317041-A1 COMPOUNDS GPR68, GPR88, GPR35 PTGDR2 115/4885CCR1 900/4885GPR119 16/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.